BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Maev IV, Samsonov AA, Palgova LK, Pavlov CS, Vovk EI, Shirokova EN, Starostin KM. Effectiveness of phosphatidylcholine in alleviating steatosis in patients with non-alcoholic fatty liver disease and cardiometabolic comorbidities (MANPOWER study). BMJ Open Gastroenterol 2020;7:e000341. [PMID: 32095253 DOI: 10.1136/bmjgast-2019-000341] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Moosavian SA, Sathyapalan T, Jamialahmadi T, Sahebkar A. The Emerging Role of Nanomedicine in the Management of Nonalcoholic Fatty Liver Disease: A State-of-the-Art Review. Bioinorg Chem Appl 2021;2021:4041415. [PMID: 34659388 DOI: 10.1155/2021/4041415] [Reference Citation Analysis]
2 Dajani AI, Abuhammour A. Agents for the treatment of fatty liver disease: focus on essential phospholipids. Drugs Ther Perspect 2021;37:249-64. [DOI: 10.1007/s40267-021-00838-x] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Lu Y, Feng T, Zhao J, Jiang P, Xu D, Zhou M, Dai M, Wu J, Sun F, Yang X, Lin Q, Pan W. Polyene Phosphatidylcholine Ameliorates High Fat Diet-Induced Non-alcoholic Fatty Liver Disease via Remodeling Metabolism and Inflammation. Front Physiol 2022;13:810143. [PMID: 35295576 DOI: 10.3389/fphys.2022.810143] [Reference Citation Analysis]
4 Osipova D, Kokoreva K, Lazebnik L, Golovanova E, Pavlov C, Dukhanin A, Orlova S, Starostin K. Regression of Liver Steatosis Following Phosphatidylcholine Administration: A Review of Molecular and Metabolic Pathways Involved. Front Pharmacol 2022;13:797923. [DOI: 10.3389/fphar.2022.797923] [Reference Citation Analysis]